{
    "2021-01-21": [
        [
            {
                "time": "2021-01-21",
                "original_text": "药明康德：超预期，看好2021年高增长延续、天花板提升",
                "features": {
                    "keywords": [
                        "药明康德",
                        "超预期",
                        "高增长",
                        "天花板提升"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-01-21",
                "original_text": "盘后公告集锦|东方日升与福莱特签订近90亿元光伏玻璃重大销售合同 药明康德、江铃汽车年度净利大幅预增",
                "features": {
                    "keywords": [
                        "药明康德",
                        "净利大幅预增",
                        "光伏玻璃",
                        "销售合同"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物",
                        "新能源"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-01-21",
                "original_text": "【盈喜】药明康德(02359-HK)料年度盈利50%到60%",
                "features": {
                    "keywords": [
                        "药明康德",
                        "年度盈利",
                        "50%-60%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-01-21",
                "original_text": "药明康德(603259.SH)2020年度净利润预增50%-60%",
                "features": {
                    "keywords": [
                        "药明康德",
                        "2020年度",
                        "净利润预增",
                        "50%-60%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-01-21",
                "original_text": "药明康德：预计2020年净利润同比增长50%至60%",
                "features": {
                    "keywords": [
                        "药明康德",
                        "2020年",
                        "净利润",
                        "同比增长",
                        "50%-60%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-01-21",
                "original_text": "天演药业赴美IPO：药明康德持股10.8%，产品尚未上市亏损持续扩大 亏损",
                "features": {
                    "keywords": [
                        "天演药业",
                        "赴美IPO",
                        "药明康德",
                        "持股10.8%",
                        "亏损持续扩大"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-01-21",
                "original_text": "医药生物行业周报：国家医保局发布“两定办法”",
                "features": {
                    "keywords": [
                        "医药生物",
                        "国家医保局",
                        "两定办法"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-01-21",
                "original_text": "医药生物行业：高景气CXO行业或持续高增长 多个CXO公司发布2020业绩预告 数据超预期",
                "features": {
                    "keywords": [
                        "医药生物",
                        "CXO行业",
                        "高增长",
                        "业绩预告",
                        "数据超预期"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}